Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.55 |
| ▸ | CSF1R | P07333 | 4/20 | 0.54 |
| ▸ | RAF1 | P04049 | 4/20 | 0.54 |
| ▸ | KIT | P10721 | 5/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | USP36 | Q9P275 | 4/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358527 | 0.86 | HDAC3 (0.58) | BRAFCSF1RKITMAPK14LCK | |
| SCHEMBL22025295 | 0.84 | PTGS1 (0.64) | BRAFKITBTK | |
| SCHEMBL29921719 | 0.84 | BRAF (0.54) | BRAFCSF1RRAF1KITMAPK14 | |
| SCHEMBL29071356 | 0.84 | BRAF (0.54) | BRAFCSF1RRAF1KITMAPK14 | |
| SCHEMBL1409060 | 0.83 | BRAF (0.61) | BRAFCSF1RRAF1KITMAPK14 | |
| SCHEMBL374471 | 0.82 | PTGS1 (0.70) | BRAFCSF1RKITMAPK14LCK | |
| SCHEMBL19500736 | 0.82 | BRAF (0.53) | BRAFCSF1RRAF1KITMAPK14 | |
| SCHEMBL4421974 | 0.81 | CSF1R (0.52) | BRAFCSF1RKITMAPK14LCK | |
| Hydrochloric Acid SCHEMBL5004557 | 0.81 | PTGS1 (0.68) | BRAFCSF1RKITMAPK14LCK | |
| SCHEMBL12465329 | 0.81 | P2RY14 (0.53) | BRAFCSF1RKITMAPK14LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | claimed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2022178256-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | disclosed |
| EP-2295424-A1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | Natco Pharma Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LIMITED (IN) | 2007-10-04 | — | — | US | disclosed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | ABL1, ABL2, BCR | BRAF 95/4885CSF1R 524/4885RAF1 81/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | BRAF 680/4885CSF1R 4503/4885RAF1 2041/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | BRAF 35/4885CSF1R 576/4885RAF1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.